A clinical trial on triglyceride-lowering in subjects with moderate hypertriglyceridemia (200–500 mg/dl) by olezarsen showed much more marked reductions in APOC3 (74% for the highest dose of olezarsen) and a 58% reduction in VLDL-cholesterol, and olezarsen also modestly lowered plasma APOB levels by 10% (82). Here, APOC3 is linked to hypertriglyceridemia.